A phase I/II trial of recombinant interleukin-2 in AIDS/ARC: alterations of phenotypes of peripheral blood mononuclear cells.
In the context of a clinical phase I/II trial with recombinant interleukin 2 (rIL-2) surface phenotypes of peripheral blood leukocytes and delayed-type hypersensitivity skin reactions were monitored in four patients with acquired immunodeficiency syndrome (AIDS) and three patients with AIDS-related complex (ARC). The phenotypic alterations during the 14-day course of treatment were characterized by 1. a decrease in the proportion of OKT9 positive lymphocytes in AIDS patients, 2. an increase in the proportion of Leu8-/Leu3a+ lymphocytes in all patients and, in particular, 3. the transient significant decrease of the Leu7+/OKT3+ ratio, which was elevated pretherapeutically in AIDS patients (0.78 +/- 0.21) and ARC patients (0.48 +/- 0.06) compared to healthy controls (0.18 +/- 0.08). In contrast, the T4/T8 ratio of the patients' T-cells was not significantly affected by rIL-2 treatment. Delayed skin reactivity to recall antigens was improved in some patients. In one patient the surface phenotypes of peripheral blood mononuclear cells were determined on the first day of rIL-2 treatment in the morning before and in the evening after infusion of rIL-2. A rise of HLA-DR positive non-B-lymphocytes was observed. We conclude that the Leu7/OKT3 ratio, OKT9 and HLA-DR may be useful markers for monitoring the effects of biological response modifiers in patients with AIDS/ARC.
D000386:AIDS-Related Complex / Q000097:blood / Q000276:immunology / Q000628:therapy*; D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000276:immunology / Q000628:therapy*; D002462:Cell Membrane / Q000276:immunology; D004341:Drug Evaluation; D006684:HLA-DR Antigens; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000627:therapeutic use*; D007962:Leukocytes / Q000276:immunology; D010641:Phenotype; D012882:Skin Tests
D006684:HLA-DR Antigens; D007376:Interleukin-2